The perils of clinical trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24682123.
- Also identified by DOI 10.1038/ki.2013.406.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When the maximal reabsorptive capacity for glucose is lowered by blockade of the activity of sodium-glucose cotransporter-2 (SGLT2), glucosuria occurs in proportion to the plasma glucose and glomerular filtration rate. Accordingly, the modest, 0.44%, hemoglobin A1c reduction found by Kohan et al. in diabetic patients with relatively good glycemic control and chronic kidney disease stage 3 treated with an SGLT2 inhibitor might have been anticipated. The 0.32% fall in hemoglobin A1c in the placebo group, however, seems less expected.
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Glucosides